Assertio (ASRT) Competitors $0.79 +0.02 (+2.05%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.78 0.00 (-0.61%) As of 08/22/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASRT vs. CGC, DMAC, OCGN, DSGN, RNAC, DRUG, NGNE, HUMA, PBYI, and ACBShould you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Canopy Growth (CGC), DiaMedica Therapeutics (DMAC), Ocugen (OCGN), Design Therapeutics (DSGN), Cartesian Therapeutics (RNAC), Bright Minds Biosciences (DRUG), Neurogene (NGNE), Humacyte (HUMA), Puma Biotechnology (PBYI), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry. Assertio vs. Its Competitors Canopy Growth DiaMedica Therapeutics Ocugen Design Therapeutics Cartesian Therapeutics Bright Minds Biosciences Neurogene Humacyte Puma Biotechnology Aurora Cannabis Canopy Growth (NASDAQ:CGC) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment. Which has more risk and volatility, CGC or ASRT? Canopy Growth has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Assertio has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Is CGC or ASRT more profitable? Assertio has a net margin of -36.97% compared to Canopy Growth's net margin of -155.76%. Assertio's return on equity of -38.19% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Canopy Growth-155.76% -89.93% -44.24% Assertio -36.97%-38.19%-15.45% Which has preferable earnings & valuation, CGC or ASRT? Assertio has lower revenue, but higher earnings than Canopy Growth. Assertio is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCanopy Growth$225.65M1.35-$429.86M-$3.03-0.42Assertio$124.96M0.61-$21.58M-$0.45-1.75 Do insiders and institutionals believe in CGC or ASRT? 3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Comparatively, 4.0% of Assertio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer CGC or ASRT? In the previous week, Canopy Growth had 1 more articles in the media than Assertio. MarketBeat recorded 3 mentions for Canopy Growth and 2 mentions for Assertio. Canopy Growth's average media sentiment score of 0.89 beat Assertio's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assertio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer CGC or ASRT? Assertio has a consensus price target of $2.38, suggesting a potential upside of 202.24%. Given Assertio's stronger consensus rating and higher probable upside, analysts clearly believe Assertio is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33Assertio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAssertio beats Canopy Growth on 10 of the 16 factors compared between the two stocks. Get Assertio News Delivered to You Automatically Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASRT vs. The Competition Export to ExcelMetricAssertioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.63M$2.53B$5.81B$9.76BDividend YieldN/A1.67%4.39%4.06%P/E Ratio-1.7522.9031.3626.05Price / Sales0.61516.56387.8788.42Price / Cash16.01179.1038.0259.36Price / Book0.815.939.536.60Net Income-$21.58M$31.83M$3.26B$265.65M7 Day Performance-3.36%1.89%2.14%2.00%1 Month Performance4.84%1.62%3.22%0.46%1 Year Performance-38.61%9.25%30.18%18.88% Assertio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASRTAssertio2.0191 of 5 stars$0.79+2.1%$2.38+202.2%-38.6%$75.63M$124.96M-1.7520CGCCanopy Growth0.7337 of 5 stars$1.37+5.4%N/A-79.5%$311.80M$225.65M-0.453,150Short Interest ↑DMACDiaMedica Therapeutics1.5316 of 5 stars$5.76-4.5%$12.33+114.1%+52.8%$311.68MN/A-8.3520Short Interest ↑OCGNOcugen1.0673 of 5 stars$1.04-1.0%$6.00+476.9%-22.3%$306.92M$4.05M-5.2080DSGNDesign Therapeutics0.1635 of 5 stars$5.40+1.3%N/A+7.6%$303.53MN/A-4.8240RNACCartesian Therapeutics2.6079 of 5 stars$11.28-0.4%$40.00+254.6%-18.3%$294.60M$38.91M-0.2164Positive NewsGap UpDRUGBright Minds Biosciences2.6698 of 5 stars$45.55+8.9%$83.25+82.8%+4,252.5%$294.58MN/A-48.98N/ATrending NewsAnalyst ForecastAnalyst RevisionNGNENeurogene1.7182 of 5 stars$20.45-0.3%$46.17+125.8%-42.8%$292.72M$930K-4.7490HUMAHumacyte2.3384 of 5 stars$1.80-4.3%$10.64+491.3%-77.5%$291.62M$1.57M-4.00150Insider TradeGap DownPBYIPuma Biotechnology4.0836 of 5 stars$5.01-12.6%$7.00+39.7%+106.7%$288.63M$238.06M5.11200High Trading VolumeACBAurora Cannabis0.8031 of 5 stars$5.12+0.8%N/A-23.3%$286.79M$246.72M-26.951,130 Related Companies and Tools Related Companies Canopy Growth Competitors DiaMedica Therapeutics Competitors Ocugen Competitors Design Therapeutics Competitors Cartesian Therapeutics Competitors Bright Minds Biosciences Competitors Neurogene Competitors Humacyte Competitors Puma Biotechnology Competitors Aurora Cannabis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASRT) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.